Neil Goldsmith
Director Strategy, BaseLaunch
Neil is a serial entrepreneur with broad experience of the life science sector. He has founded, or otherwise been instrumental in the early development of multiple biotech ventures over the last 35 years, including Evolva (synthetic biology, founder & CEO, IPO Zurich) , TopoTarget (oncology, founder, IPO Copenhagen) , Biotage (microwave chemistry, founder, IPO Stockholm), PNAD (DNA diagnostics, CEO, trade sale), BIAcore (biosensors, VP Bus Dev, IPO NASDAQ) and Scientific Generics (head of marketing, IPO LSE).
In addition to Base aunch, Neil is currently a board member of Alentis Therapeutics (anti-fibrotic therapeutics), Unibio plc (protein from methane) and Sundew ApS (treating water transmitted diseases). Neil has a first-class degree in Zoology from the University of Oxford, and set-up his first venture straight out of university, benefitting from a very early venture accelerator that was run by the University of Stirling.